Madrigal Pharmaceuticals Financial Ratios
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Madrigal Pharmaceuticals ratio analysis
Madrigal Pharmaceuticals earned a net margin of -30.1% in FY 2025, up from -258.6% a year earlier. Return on equity reached -47.8%, meaning Madrigal Pharmaceuticals generated -0.48 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.56 versus 0.16 the year before, and the current ratio was 4.01.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Madrigal Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 17.60 | 47.75 | — | — | — | — | — | — | — | — |
| Price / book | 27.99 | 11.40 | 12.31 | 25.20 | 7.15 | 7.16 | 3.21 | 3.48 | 6.17 | 2.13 |
| Gross margin | — | 96.5% | — | — | — | — | — | — | — | — |
| Operating margin | -31.3% | -276.4% | — | — | — | — | — | — | — | — |
| Net margin | -30.1% | -258.6% | — | — | — | — | — | — | — | — |
| Free cash flow margin | -19.8% | -253.7% | — | — | — | — | — | — | — | — |
| Return on equity (ROE) | -47.8% | -61.8% | -92.2% | -149.6% | -123.3% | -84.3% | -20.2% | -6.9% | -17.1% | -72.5% |
| Return on assets (ROA) | -22.9% | -44.7% | -58.3% | -81.5% | -88.5% | -70.5% | -19.0% | -6.8% | -16.2% | -64.0% |
| Debt / equity | 0.56 | 0.16 | 0.28 | 0.25 | 0.00 | — | — | — | — | — |
| Current ratio | 4.01 | 6.10 | 5.38 | 3.12 | 3.54 | 6.13 | 17.52 | 57.46 | 19.10 | 8.58 |
| Revenue growth | 432.1% | — | — | — | — | — | — | — | — | — |